2022
Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding
Li D, Ong S, Hughes M, Hung K, Agarwal R, Alexis J, Damianos J, Sharma S, Pires J, Nanna M, Laine L. Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding. Alimentary Pharmacology & Therapeutics 2022, 57: 94-102. PMID: 36394111, DOI: 10.1111/apt.17278.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsGastrointestinal bleedingPrimary preventionCardiovascular eventsRisk of MACEYale-New Haven HospitalPrimary cardiovascular preventionAdverse cardiovascular eventsKaplan-Meier curvesLong-term outcomesRisk-benefit ratioLog-rank testAspirin 81Hospitalised patientsPrimary endpointSecondary endpointsCardiovascular preventionSubsequent hospitalisationMedian ageDeprescriptionHigh riskAspirinHospitalisationPatientsPrevention
2021
Gastrointestinal Injury Caused by Aspirin or Clopidogrel Monotherapy Versus Dual Antiplatelet Therapy ∗
Bittl JA, Laine L. Gastrointestinal Injury Caused by Aspirin or Clopidogrel Monotherapy Versus Dual Antiplatelet Therapy ∗. Journal Of The American College Of Cardiology 2021, 79: 129-131. PMID: 34752903, DOI: 10.1016/j.jacc.2021.10.027.Commentaries, Editorials and Letters
2007
Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials
McQuaid K, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. American Journal Of Ophthalmology 2007, 143: 194. DOI: 10.1016/j.ajo.2006.11.002.Peer-Reviewed Original Research
2004
Guidelines for the appropriate use of non‐steroidal anti‐inflammatory drugs, cyclo‐oxygenase‐2‐specific inhibitors and proton pump inhibitors in patients requiring chronic anti‐inflammatory therapy
Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non‐steroidal anti‐inflammatory drugs, cyclo‐oxygenase‐2‐specific inhibitors and proton pump inhibitors in patients requiring chronic anti‐inflammatory therapy. Alimentary Pharmacology & Therapeutics 2004, 19: 197-208. PMID: 14723611, DOI: 10.1111/j.0269-2813.2004.01834.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProton pump inhibitorsCost of NSAIDsPump inhibitorsGastrointestinal eventsChronic anti-inflammatory therapyRAND/UCLA Appropriateness MethodNon-steroidal anti-inflammatory drugsAnti-inflammatory therapyAnti-inflammatory drugsDrug treatment strategiesCommunity-based settingsCardiovascular riskProphylactic useAppropriateness MethodTreatment strategiesLower riskNSAIDsPatientsClinical scenariosAspirinAppropriate useInhibitorsRiskCare entitiesLiterature review
2003
Do NSAIDs induce esophagitis? The effect of non-specific NSAIDs and COX-2 specific inhibitors±low-dose aspirin in prospective, randomized, double-blind, placebo-controlled endoscopic trials
Laine L, Goldstein J, Fort J. Do NSAIDs induce esophagitis? The effect of non-specific NSAIDs and COX-2 specific inhibitors±low-dose aspirin in prospective, randomized, double-blind, placebo-controlled endoscopic trials. Gastroenterology 2003, 124: a511. DOI: 10.1016/s0016-5085(03)82586-6.Peer-Reviewed Original ResearchProton pump inhibitor use in patients with indications for low-dose aspirin who start COX-2 selective inhibitors or nonselective NSAIDs
Ofman J, Knight K, Badamgarav E, Henning J, Wallace K, Wong J, Dylan M, Laine L. Proton pump inhibitor use in patients with indications for low-dose aspirin who start COX-2 selective inhibitors or nonselective NSAIDs. Gastroenterology 2003, 124: a107. DOI: 10.1016/s0016-5085(03)80529-2.Peer-Reviewed Original Research